Emerging targets in human lymphoma: targeting the MYD88 mutation
B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link between TLR signaling and B cell neoplasm. Recurrent oncogenic mutations in MYD88 have been found in 39% of the activated B cell-like subtype of diffuse large B cell lymphoma (ABC DLBCL). Interestingly, 29% of ABC DLBCL have a single amino acid...[Show more]
|Collections||ANU Research Publications|
|Source:||Blood and Lymphatic Cancer: Targets and Therapy|
|01_Jeelall_Emerging_targets_in_human_2013.pdf||Published Version||314.74 kB||Adobe PDF|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.